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1. Introduction 
Much interest of late has centered around RNA- 
directed DNA synthesis. Initially, with the finding of 
an RNA-dependent DNA polymerase in oncogenic 
RNA viruses [l-S] and what was described as the 
exclusive presence of the polymerase in acute leukemia 
cells as opposed to ‘normal’ cells [6] , speculation as 
to a molecular basis for leukemogenesis and a predictive 
test for leukemia bounded. However, with the iden- 
tification [7, S] of the polymerase in ‘normal’ cells 
(cells not known to be RNA virally transformed) the 
hope of an absolute predictive index for leukemia or 
neoplasia has lost credibility, and the RNA-dependent 
DNA polymerase may be of more interest from the 
standpoint of gene amplification as opposed to a 
neoplastic predictor. In our studies of this polymerase 
we have undertaken an extensive, systematic experi- 
ment designed to note the effects of a number of 
potential inhibitors (primarily antibiotics) on the RNA- 
dependent DNA polymerase in vitro. The present 
brief report gives the results of these experiments. 
Several compounds were shown to be potent inhibitors 
of an RNA-dependent DNA from mouse leukemia 
cells. 
2. Materials and methods 
Two cell lines were utilized, L5 178Y cells grown 
in suspension culture and L1210 cells harvested from 
CDFr mice. Details of cell culture and harvest are 
given in previous publications [9-l 1] . All cells were 
used in logarithmic growth. A ‘nucleic acid free extract’ 
of the L5 I78Y cells was prepared by the method of 
Gal10 et al. [6] as described previously [8] . Exponen- 
tial L5 178Y cells were vigorously homogenized for 
30 strokes ir. a Potter Elvehjem homogenizer at 0’. 
The homogenizing solution was 5 volumes of 25 mM 
tris-HCl buffer pH 8.3, 1 mM MgCIZ ,6 mM NaCl, 5 
mM dithiothreitol and 0.15 mM EDTA. The samples 
were centrifuged at 27,000 g and the pellet discarded. 
Nucleic acids were removed from the supernatant 
by successive precipitations with MgCl, and protamine 
sulfate. This crude preparation was utilized as the 
enzyme source in this report. Details of the enzyme 
are given in the legend to table 1. Crude polymerase 
from L1210 cells was prepared by the method of 
Scolnick et al. [7] and stored overnight at -20” to 
reduce levels of a labile inhibitor, 
3. Results and discussion 
The data (see table 1) indicate that several of the 
compounds tudied were inhibitory to the RNA- 
directed DNA polymerase. The order of greatest in- 
hibition was adriamycin > daunomycin > prothidium 
Br > anthramycin > neomycin z mitomycin ” hydroxy- 
urea !Z ethidium Br z formamidoxime > azaserine >
camptothecin > carbidium sulfate. None of the 
following compounds inhibited the polymerase ven 
at 100 /&II!: actinomycin D, antimycin, carbomycin, 
chloramphenicol, cycloheximide, kanamycin, oleando- 
mycin, rutamycin, valinomycin, vancomycin. The 
effect of the drug was essentially the same on each of 
the three enzymes. Azaserine, an antineoplastic agent 
[ 12,131 and an agent used to delay kidney graft 
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Table 1 
Inhibition of an RNA-dependent DNA polymerase. 
System 
Dw 
concn 
(wg/ml) 
Enzyme 
L5178Y Ia L5178Y IIb ~1210 111c 
(cpm/protein) % (cpm/mg protein) % (cpm/mg protein) % 
Complete 
Minus template 
Adriamycin 
Anthramycin 
Camptothecin 
Daunomycin 
Mitomycin 
Neomycin 
Ethidium Br 
Prothidium Br 
Carbidium 
sulfate 
Hydroxyurea 
Formamidoxine 
Azaleucine 
Azaserine 
0 
0 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
1 
10 
100 
2500 5600 3240 
0 0 580 (1’3jd 
2119 
1414 
211 
85 4718 
57 2381 
12 581 
100 5100 
90 4811 
57 2801 
100 5504 
77 4816 
64 4219 
81 4089 
28 2119 
19 1409 
100 5413 
90 4281 
61 2909 
96 5223 
61 4298 
57 3971 
100 5439 
77 4811 
68 4011 
101 5709 
59 3914 
48 2711 
100 5609 
88 4810 
77 4018 
100 5509 
76 2091 
62 4062 
101 5477 
77 4981 
56 4516 
124 7100 
297 10,982 
408 16,863 
84 -e 
43 2000 
10 630 
91 - 
86 2700 
50 1900 
98 - 
86 - 
75 2300 
73 - 
38 2080 
25 680 
97 - 
16 - 
52 - 
93 - 
17 - 
71 - 
97 - 
86 - 
72 - 
102 - 
70 - 
48 - 
62 
19 
2499 
2223 
1419 
83 
59 
2501 
1921 
1591 71 
2019 
692 
481 
64 
21 
2506 
2249 
1518 
2409 
1519 
1419 
2500 
1920 
1710 
2516 
1480 
1210 
2506 
2192 
1911 
2509 
1910 
1540 
2518 
1920 
1411 
100 - 
86 - 
12 - 
98 - 
91 - 
73 - 
98 - 
89 - 
81 - 
3090 
7429 
10,298 
127 - 
196 - 
287 
2509 100 5600 100 - 
2413 97 4817 86 - 
1717 69 3509 63 - 
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rejection [ 141, had no effect on the RNA-directed 
DNA polymerase; the reason for this is not known, 
especially since the other aza-amino acid studied, 
: ~aleucine, caused an acceleration of the RNA-directed 
ilNA polymerase. 
The most potent inhibitors, adriamycin and 
daunomycin, are very closely related structurally. 
Adriamycin inhibits DNA and RNA synthesis [ 151 ; 
daunomycin has been demonstrated to bind to RNA 
and DNA [ 161 . At 100 ~.cg per ml, adriamycin in- 
hibited the L5 178Y RNA (rA.dT) directed DNA 
polymerase 90%; daunomycin inhibited the “same 
polymerase 75%. The action of these drugs presumably 
is caused by the binding of these agents to the 
template or to the template-product. 
Ethidium Br and the related phenanthridium com- 
, pounds carbidium sulfate and prothidium Br inhibit 
nucleic acid synthesis in HeLa cells [ 171, L5 178Y 
cells [ 181, and bacteria [ 191. Ethidium Br is known 
to intercalate between the bases of DNA and cause 
uncoiling and reverse coiling of DNA [20,21] . The 
three compounds inhibited the RNA-directed DNA 
synthesis at 100 pg per ml between .52 and 38% in the 
I.5 178Y II system (table 1). 
Anthramycin, which was moderately inhibitory 
to the RNA-directed DNA polymerase in all systems, 
binds to DNA but not RNA [22] . Camptothecin 
inhibits mammalian DNA synthesis [23] but does 
not bind to DNA [24]. Mitomycin binds to DNA 
Footnotes to table 1 
- 
strands forming crosslinks [25] . Each of these anti- 
biotics could inhibit the RNA-directed DNA polymer- 
ase by binding to the template or to the template 
product. Neomycin, an aminoglycoside antibiotic, 
causes misreading of mRNA [26] , its inhibition of 
the RNA-dependent DNA polymerase reported herein 
is not consistent with this mechanism of action. 
Hydroxyurea and formamidoxime are similar com- 
pounds; both inhibit the mouse leukemic cell RNA- 
directed DNA polymerase. Hydroxyurea is a potent 
inhibitor of DNA synthesis [27,28] ; whether this in- 
hibition is at the polymerase level is not known. 
Data presented herein describe some inhibitors 
of the RNA-dependent DNA polymerase. Potential 
uses of these inhibitors are as tools for specific inhibition 
of this polymerase as opposed to the DNA-directed 
DNA polymerase and for therapeutic use, if indeed 
this enzyme proves to be important in leukemogenesis. 
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a The complete system contained in a final volume of 1 ml of the following: 0.50 mg protein from the ‘nucleic acid free’ extract 
(‘enzyme’); 1.0 pmole each of dATP, dCfP, and dGTP; 50 Mmoles tris-HCl buffer, pH 8.5; 5.0 nmoles MgCla; 10 PCi 3H- 
methyl-TTP (7 Ci/mmole, New England Nuclear), 20 pmoles dithiothreitol; 50 pmoles NaCl; and 36 @ of rat liver RNA 
(‘template’). Assays were incubated at 37” for 2 hr, after which 1 mg of yeast RNA was added and the assay was made 10% in 
trichloroacetic acid. The resultant precipitates were washed 3 times with 10% trichloroacetic acid, dissolved in 1 N NaOH at 
loo”, plated on a glass fiber filter and counted in a liquid scintillation counter. Rat liver RNA (template) was purchased from 
General Biochemicals and treated with DNase and the enzyme removed by phenol extraction. DNase and RNase were purchased 
from Worthington. All data are given with endogenous activity (about 10%) determined with water substituted for the 
‘template’ subtracted. The complete system also contained 50 ~1 of distilled HsO, for drug assays the drug was present in this 
50 f.d. 
b The complete system was exactly as in (a) except 0.01 AaeorA’ dT was substituted for the rat liver RNA as template. 
c Leukemia L1210 cells were isolated [9] from CDFt mice, and the crude polymerase prepared as described by Scolnick et al. 
[7]. The cell extract was stored overnight at -20” to reduce levels of a labile inhibitor of the reaction. The complete system, 
in a fmal volume of 100 bl, contained: 20 mM TES buffer, pH 7.4; 60 mM KCl, 1 mM Mn acetate; 2 mM dithiothreitol; 0.01 
AaeorAarU; 10 fig enzyme protein and 10 &i 3H-TTP. Incubations were terminated after 60 min at 37” by addition of 5% 
trichloroacetic acid. The precipitates were washed with 5% trichloroacetic acid (4”) 70% ethanol and 99% ethanol, on Mill&ore 
filters (HA), then radioactivity was measured by liquid scintillation counting. 
d Percent the drug assay is of the complete. 
e Experiment not performed. 
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